Literature DB >> 23959270

Lung cancer: Maintenance therapy and precision medicine in NSCLC.

Rafael Rosell1, Niki Karachaliou.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23959270     DOI： 10.1038/nrclinonc.2013.152

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.

Authors:  Virginie Westeel; Elisabeth Quoix; Denis Moro-Sibilot; Mariette Mercier; Jean-Luc Breton; Didier Debieuvre; Philippe Richard; Mary-Anne Haller; Bernard Milleron; Dominique Herman; Marie-Claude Level; François-Xavier Lebas; Marc Puyraveau; Alain Depierre
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

2.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

3.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

4.  Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

Authors:  Fabrice Barlesi; Arnaud Scherpereel; Achim Rittmeyer; Antonio Pazzola; Neus Ferrer Tur; Joo-Hang Kim; Myung-Ju Ahn; Joachim G J V Aerts; Vera Gorbunova; Anders Vikström; Elaine K Wong; Pablo Perez-Moreno; Lada Mitchell; Harry J M Groen
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

5.  Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Authors:  S S Pullamsetti; G A Banat; A Schmall; M Szibor; D Pomagruk; J Hänze; E Kolosionek; J Wilhelm; T Braun; F Grimminger; W Seeger; R T Schermuly; R Savai
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

7.  Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Authors:  Charli L Dominguez; Desiree H Floyd; Aizhen Xiao; Garrett R Mullins; Benjamin A Kefas; Wenjun Xin; Melissa N Yacur; Roger Abounader; Jae K Lee; Gabriela Mustata Wilson; Thurl E Harris; Benjamin W Purow
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397

8.  Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Authors:  Marianne C Nicolson; Dean A Fennell; David Ferry; Kenneth O'Byrne; Riyaz Shah; Vanessa Potter; Geraldine Skailes; Sunil Upadhyay; Paul Taylor; Valerie André; Tuan S Nguyen; Scott P Myrand; Carla Visseren-Grul; Mayukh Das; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

Review 9.  Genetics and biomarkers in personalisation of lung cancer treatment.

Authors:  Rafael Rosell; Trever G Bivona; Niki Karachaliou
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321
  9 in total
  27 in total

1.  Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.

Authors:  Dingmiao Wang; Ting Hao; Yang Pan; Xiaowei Qian; Daixing Zhou
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

2.  Elevated expression of USP9X correlates with poor prognosis in human non-small cell lung cancer.

Authors:  You Wang; Yu Liu; Bo Yang; Hong Cao; Chun-Xu Yang; Wen Ouyang; Shi-Min Zhang; Gui-Fang Yang; Fu-Xiang Zhou; Yun-Feng Zhou; Cong-Hua Xie
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

3.  Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer.

Authors:  Kai-Ze Zhong; Wei-Wen Chen; Xiao-Yan Hu; An-Li Jiang; Jian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer.

Authors:  Ze Zhang; Quan Wang; Feng Chen; Jun Liu
Journal:  Tumour Biol       Date:  2014-10-25

5.  Physicochemical Characterization and Biopharmaceutical Evaluation of ZWF: A Novel Anticancer Drug for the Treatment of Non-small Cell Lung Cancer.

Authors:  Lina Zhao; Li He; Yuan Chen; Tongchao Xia; Le Li; Shengyan Wang; Xu Bao; Junyi Yang
Journal:  AAPS PharmSciTech       Date:  2021-07-23       Impact factor: 3.246

6.  Downregulation of the long non-coding RNA TUSC7 promotes NSCLC cell proliferation and correlates with poor prognosis.

Authors:  Zhongwei Wang; Yingying Jin; Hongtao Ren; Xiulong Ma; Baofeng Wang; Yali Wang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 7.  Predicting resistance by selection of signaling pathways.

Authors:  Niki Karachaliou; Rafael Rosell; Miguel Angel Molina; Santiago Viteri
Journal:  Transl Lung Cancer Res       Date:  2014-04

8.  Overexpression of the long noncoding RNA CCAT1 promotes metastasis via epithelial-to-mesenchymal transition in lung adenocarcinoma.

Authors:  Heping Lin; Wei Cheng; Hanhan Yan; Xiaodiao Zhang
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

9.  Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells.

Authors:  Tao Tian; Jinpeng Sun; Jianxin Wang; Yanchun Liu; Haitao Liu
Journal:  Oncol Lett       Date:  2018-08-21       Impact factor: 2.967

10.  Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC.

Authors:  John Wen-Cheng Chang; Chun-Liang Shih; Chih-Liang Wang; Ji-Dung Luo; Chih-Wei Wang; Jia-Juan Hsieh; Chia-Jung Yu; Chiuan-Chian Chiou
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.